Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Akihito Kawazoe"'
Autor:
Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Masahiro Tsuda, Kaori Hino, Noboru Yamamoto, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akira Ooki
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part of
Externí odkaz:
https://doaj.org/article/7dbdc5c5725f466f9c680a126d352047
Autor:
Naoya Sakamoto, Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara, Yoshiaki Nakamura, Daisuke Kotani, Masashi Wakabayashi, Shohei Koyama, Hiroyoshi Nishikawa, Yosuke Tanaka, Shogo Takei, Itaru Endo, Motohiro Kojima, Toshihide Ueno, Hiroyuki Mano, Shota Fukuoka, Yi-Tzu Lin, Hiroki Hara, Shinya Kojima
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background Immune checkpoint inhibitor (ICI) combinations represent an emerging treatment strategies in cancer. However, their efficacy in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer (CRC) is variable. Here, a m
Externí odkaz:
https://doaj.org/article/2be9529f9843474fb27cb25f1bcfd88c
Autor:
Mashiro Okunaka PhD, Daisuke Kotani MD, PhD, Saori Mishima MD, PhD, Maho Nakamura, Akihito Kawazoe MD, PhD, Hideaki Bando MD, PhD, Takayuki Yoshino MD, PhD, Kohei Shitara MD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Purpose: Anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) is the key drug for RAS / BRAF V600E wild-type metastatic colorectal cancer (mCRC). However, anti-EGFR mAb-induced skin fissures often affect a patient’s quality of
Externí odkaz:
https://doaj.org/article/800ea98d6da648fbacb4c6dc3c67532d
Autor:
Akihito Kawazoe, Kohei Shitara, Sara Lonardi, Filippo Pietrantonio, Samuel J Klempner, Thierry André, Massimiliano Salati, Margherita Ambrosini, Giovanni Randon, Romain Cohen, Paolo Manca, Vincenzo Nasca, Joseph Chao, Leonardo Provenzano, Yu Aoki, Steven B Maron, Riccardo Cerantola, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Valerie Zhu, Darren Cowzer, Virginia Genovesi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Subgroup analyses of randomized trials suggest the superiority of immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gast
Externí odkaz:
https://doaj.org/article/f743b9a859bf4ca78c1d5072f84a6e85
Autor:
Kimimasa Sasaki, Shin Kobayashi, Masashi Kudo, Motokazu Sugimoto, Shinichiro Takahashi, Yoshiaki Nakamura, Akihito Kawazoe, Kohei Shitara, Takahiro Kinoshita, Naoto Gotohda
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract Background Immune checkpoint inhibitors (ICIs) are emerging agents used for the treatment of various malignant tumors. As ICIs are generally used for unresectable malignant tumors, there have been only a few reports of patients who underwent
Externí odkaz:
https://doaj.org/article/9147b5e980484781957977bc0fb254ed
Autor:
Mashiro Okunaka, Daisuke Kotani, Ken Demachi, Akihito Kawazoe, Takayuki Yoshino, Toshikatsu Kawasaki, Kohei Shitara
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Nanoparticle albumin-bound paclitaxel (nab-PTX) has shown non-inferiority to paclitaxel (PTX) as second-line therapy for advanced gastric cancer (AGC) with fewer infusion-related reactions. The efficacy and safety of nab-PTX plus
Externí odkaz:
https://doaj.org/article/de783cbf03f74c978acd0ae407459c17
Autor:
Akihito Kawazoe, Kohei Shitara, Chiara Cremolini, Giovanni Fucà, Sara Lonardi, Filippo Pietrantonio, Francesca Corti, Samuel J Klempner, Magali Svrcek, Thierry André, Giuseppe Curigliano, Michael Overman, Francesca Bergamo, Elisabetta Fenocchio, Massimiliano Salati, Margherita Ambrosini, Giovanni Randon, Lisa Salvatore, Romain Cohen, Raphael Colle, Priya Jayachandran, Maria Elena Elez, Marwan Fakih, Aakash Tushar Shah, Joseph Chao, Matthew Emmett, Marc Díez García, Giacomo Mazzoli, Leonardo Provenzano, Keigo Chida, Veronica Conca
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/0a3c47b59e654946a72b34ac617e8c57
Autor:
Daisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, Asumi Kaneko, Yoshiaki Nakamura, Akihito Kawazoe, Hideaki Bando, Hiroya Taniguchi, Kohei Shitara, Takashi Kojima, Akihito Tsuji, Takayuki Yoshino
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retro
Externí odkaz:
https://doaj.org/article/5353642cd7e043c7a448adae57648b7d
Autor:
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. Methods Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regime
Externí odkaz:
https://doaj.org/article/6bb077a4afc0401982a619dd6d4c130c
Autor:
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, Akihito Kawazoe, Yasutoshi Kuboki, Kohei Shitara, Takashi Kojima, Hiroya Taniguchi, Jun Watanabe, Itaru Endo, Takayuki Yoshino
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, the
Externí odkaz:
https://doaj.org/article/7aab82a13e18448aa87b6df384e86f3f